Daraxonrasib Trial: Tumours Vanish in 8% of Pancreatic Cases

A phase I/II trial reported at the EORTC-NCI-AACR symposium found 60.7% tumour shrinkage in metastatic pancreatic cancer patients taking daraxonrasib.

@sharedot

Daraxonrasib Trial: Tumours Vanish in 8% of Pancreatic Cases

By @sharedot · · 7 pages

  • Health
  • Cancer
  • Oncology
  • Clinical Trials

A phase I/II trial reported at the EORTC-NCI-AACR symposium found 60.7% tumour shrinkage in metastatic pancreatic cancer patients taking daraxonrasib.

What the trial found

Dr. Wungki Park of Memorial Sloan Kettering Cancer Center reported that 61 patients with previously untreated metastatic pancreatic cancer received 200 mg of daraxonrasib daily alongside gemcitabine and nab-paclitaxel.

bioengineer.org reports that tumours shrank significantly or became undetectable in 60.7% of participants, with 8.2% achieving a confirmed complete response on scans. Disease progression was halted in 90.2% of patients, and median progression-free survival reached 12.8 months.

Why it is surprising

Pancreatic cancer is one of oncology's hardest targets: more than half of patients are diagnosed only after the disease has spread, and standard chemotherapy historically shrinks tumours in just 23–42% of patients, with progression resuming within five to six months.

A response rate above 60%, with median progression-free survival nearly doubling historical benchmarks, breaks from what has been possible in this disease for decades. Per bioengineer.org, 76.6% of participants were alive at 12 months.

The science behind the pill

More than 90% of pancreatic cancers carry mutations in the RAS gene, which acts like a cellular switch locked in the 'on' position, driving constant division. Daraxonrasib was engineered to bind the active RAS(ON) state, disrupting the signalling that pancreatic cancer cells depend on to grow.

Independent expert Professor Elena Garralda of the Vall d'Hebron Institute of Oncology, not involved in the trial, told the symposium that targeting active RAS is a pivotal development also relevant to some lung, bowel, biliary, appendiceal and gynaecological cancers, according to bioengineer.org.

Spotting the symptoms

Women's Health lists seven possible symptoms from the NHS and Pancreatic Cancer UK: persistent indigestion or bloating, upper tummy or back pain worse after eating, unexplained weight loss, loss of appetite, changes in poo such as paler or oilier stools, nausea or vomiting, and jaundice with yellowing skin or eyes, dark pee and itchy skin.

The outlet advises urgent GP contact or NHS 111 for jaundice, and a GP visit for unexplained weight loss or symptoms not settling after two weeks.

What comes next

Because RMC-GI-102 was an early-phase study without a randomized control arm receiving chemotherapy alone, bioengineer.org notes the findings must be validated in broader comparative research.

The global phase III RASolute-303 trial, again led by Dr. Park, will now test daraxonrasib both alone and with chemotherapy directly against conventional treatment.

Caution is warranted: a complete response on scans is not a cure, and a peer-reviewed publication of the phase I/II data has not yet appeared in the source pack.

Sources

  1. bioengineer.org › Daraxonrasib Chemotherapy Combination Shows Promising Tumour Shrinkage in Metastatic Pancreatic Cancer Trial
  2. womenshealthmag.com › Pancreatic cancer can feel like indigestion – 7 signs women need to know

More on Health